

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

ACADEMIC SUPPLEMENT

Are All Atypical Antipsychotics Equal for the Treatment of Cognition and Affect in Schizophrenia?

Introduction

J. Zohar

Atypical Antipsychotics: Matching Receptor Profile to Individual Patient's Clinical Profile

D.K. Shayegan and S.M. Stahl

Cognitive Factors in Schizophrenia: Causes, Impact, and Treatment

H.Y. Meltzer

Treating the Mind and Body in Schizophrenia: Risks and Prevention

J.M. Meyer

Maximizing Function After First-Episode Psychosis

L.C. Kopala

This academic supplement is based on proceedings from the industry-supported symposium "Are All Atypical Antipsychotics Equal for the Treatment of Cognition and Affect in Schizophrenia?" presented at the 157th Annual Meeting of the American Psychiatric Association, held May 1–6, 2004, in New York City. The APA was not involved in, and received no commercial support for, the development of this product and does not award CME credit for this program.

Faculty Affiliations and Disclosures

Dr. Kopala is clinical professor of psychiatry in the Department of Psychiatry's Centre for Complex Disorders at the University of British Columbia in British Columbia, Canada. She is a consultant to, on the speaker's bureaus of, and receives grant/research support and honorarium from AstraZeneca, Bristol-Myers Squibb, Janssen, and Pfizer.

Dr. Meltzer is Bixler Professor of Psychiatry and Pharmacology and Director of the Division of Psychopharmacology in the Department of Psychiatry at Vanderbilt University Medical Center in Nashville, Tennessee. He receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer; and receives honoraria/expenses from Janssen and Pfizer.

Dr. Meyer is staff psychiatrist at the Veteran's Affairs San Diego Healthcare System and assistant adjunct professor of psychiatry in the Department of Psychiatry at the University of California, San Diego, in La Jolla. He is a consultant for and on the speakers' bureaus of Bristol-Myers Squibb, Janssen, and Pfizer; receives grant/research support from Bristol-Myers Squibb; and has received honoraria/expenses from AstraZeneca, Bristol-Myers Squibb, Janssen, and Pfizer.

Mr. Shayegan is director of research and development at the Neuroscience Education Institute in Carlsbad, CA. He receives honoraria and expenses from Pfizer.

Dr. Stahl is chairman and CEO of the Neuroscience Education Institute in Carlsbad, California, and adjunct professor of psychiatry in the Department of Psychiatry at the University of California, San Diego, in La Jolla. He is a consultant to and receives honoraria from Abbott, Asahi, AstraZeneca, Bristol-Myers Squibb, Cephalon, Cypress Biosciences, Eli Lilly, GlaxoSmithKline, Organon, Pierre Fabre, Sanofi-Synthelabo, and Wyeth; and receives grant/research support from Abbott, Asahi, AstraZeneca, Bristol-Myers Squibb, Cephalon, Cypress Biosciences, Eli Lilly, GlaxoSmithKline, Pfizer, and Wyeth.

Disclaimer

This academic supplement is supported by an unrestricted educational grant from Pfizer. Sponsorship of this review does not imply the sponsor's agreement with the views expressed herein.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher, the sponsor, nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation. This supplement may contain information concerning a use or dosage schedule that has not been approved by the US Food and Drug Administration.

Copyright ©2004 by MBL Communications, Inc.

333 Hudson St., 7th Floor, New York, NY 10013.

Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form.

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

EDITOR

Jack M. Gorman, MD
Mount Sinai School of Medicine
New York, NY

ASSOCIATE AND FOUNDING EDITOR

Eric Hollander, MD
Mount Sinai School of Medicine
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS

EUROPE

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD
University of Stellenbosch
Tygerberg, South Africa

FAR EAST

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

CONTRIBUTING AUTHORS

Lili C. Kopala, MD, FRCP
Herbert Y. Meltzer, MD
Jonathan M. Meyer, MD
Darius K. Shayegan, BS
Stephen M. Stahl, MD, PhD

SUPPLEMENT EDITOR

Joseph Zohar, MD

BOARD OF ADVISORS

NEUROLOGISTS

Mitchell F. Brin, MD
University of California, Irvine
Irvine, CA

Jeffrey L. Cummings, MD
University of California, Los Angeles
Los Angeles, CA

Jerome Engel, Jr., MD, PhD
University of California, Los Angeles
Los Angeles, CA

Mark S. George, MD
Medical University of South Carolina
Charleston, SC

Deborah Hirtz, MD
National Institute of Neurological
Disorders and Stroke, NIH
Rockville, MD

Richard B. Lipton, MD
Albert Einstein College of Medicine
Bronx, NY

C. Warren Olanow, MD, FRCP
Mount Sinai School of Medicine
New York, NY

Steven George Pavlakis, MD
Maimonides Medical Center
Brooklyn, NY

Stephen D. Silberstein, MD, FACP
Thomas Jefferson University
Philadelphia, PA

Michael Trimble, MD, FRCP, FRPsych
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

PSYCHIATRISTS

Margaret Altemus, MD
Cornell University Medical College
New York, NY

Dennis S. Charney, MD
National Institute of Mental Health
Bethesda, MD

Dwight L. Evans, MD
University of Pennsylvania
Philadelphia, PA

Siegfried Kasper, MD
University of Vienna
Vienna, Austria

Martin B. Keller, MD
Brown Medical School
Providence, RI

Lorri M. Koran, MD

Stanford University School of Medicine
Stanford, CA

Yves Lecrubier, MD
Hôpital de la Salpêtrière
Paris, France

Herbert Y. Meltzer, MD
Vanderbilt University Medical Center
Nashville, TN

Stuart A. Montgomery, MD
St. Mary's Hospital Medical School
London, United Kingdom

Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
Atlanta, GA

Humberto Nicolini, MD, PhD
National Mexican Institute of Psychiatry
Mexico City, Mexico

Stefano Pallanti, MD, PhD
University of Florence
Florence, Italy

Katharine Phillips, MD
Brown Medical School
Providence, RI

Harold A. Pincus, MD
Western Psychiatric Institute & Clinic
RAND-University of Pittsburgh Health
Institute, Pittsburgh, PA

Scott L. Rauch, MD
Massachusetts General Hospital
Charlestown, MA

Alan F. Schatzberg, MD
Stanford University School of Medicine
Stanford, CA

Thomas E. Schlaepfer, MD
University of Bonn
Bonn, Germany

Stephen M. Stahl, MD, PhD
University of California, San Diego
La Jolla, CA

Norman Sussman, MD, DFAPA
New York University Medical School
New York, NY

Karen Dineen Wagner, MD, PhD
The University of Texas Medical Branch
Galveston, Texas

Herman G.M. Westenberg, MD
University Hospital Utrecht
Utrecht, The Netherlands

Stuart C. Yudofsky, MD
Baylor College of Medicine
Houston, TX

MBL COMMUNICATIONS Corporate Staff

CEO & PUBLISHER

Darren L. Brodeur

ASSOCIATE PUBLISHER

Elizabeth Katz

MANAGING EDITOR

Christopher Naccari

SENIOR EDITOR

Deborah Hughes

DEPUTY SENIOR EDITOR

José R. Ralat

ACQUISITIONS EDITORS

Lisa Arrington

Shoshana Bauminger

ASSISTANT EDITOR

Emil J. Ross

PUBLISHING ASSOCIATE

Shelley Wong

ART DIRECTOR

Derek Oscarson

CONTROLLER

John Spano

NATIONAL ACCOUNT MANAGER

Kathleen J. Skae, MBA

INFORMATION TECHNOLOGY

Clint Bagwell Consulting

OFFICE ASSISTANT

Manuel Pavón

CORPORATION COUNSEL

Lawrence Ross, Esq.

Bressler, Amery, and Ross

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

Table of Contents

October 2004

Volume 9 – Number 10 – Supplement 11

Based on Proceedings From the 157th Annual Meeting of the American Psychiatric Association, held May 1–6, 2004, in New York City

- 5 Introduction**
Are All Atypical Antipsychotics Equal for the Treatment of Cognition and Affect in Schizophrenia?
By Joseph Zohar, MD
- 6 Atypical Antipsychotics: Matching Receptor Profile to Individual Patient's Clinical Profile**
By Darius K. Shayegan, BS, and Stephen M. Stahl, MD, PhD
- 15 Cognitive Factors in Schizophrenia: Causes, Impact, and Treatment**
By Herbert Y. Meltzer, MD
- 25 Treating the Mind and Body in Schizophrenia: Risks and Prevention**
By Jonathan M. Meyer, MD
- 34 Maximizing Function After First-Episode Psychosis**
By Lili C. Kopala, MD, FRCPC
- CONTINUING MEDICAL EDUCATION**
- 40 CME quiz accredited by Mount Sinai School of Medicine for 3.0 category 1 credits toward the AMA Physician's Recognition Award.**

Founded in 1996, *CNS Spectrums* is an *Index Medicus* journal and is available on MEDLINE under the citation *CNS Spectr.* It is available online at www.cnsspectrums.com.

CNS Spectrums (ISSN 1092-8529) is published monthly by MBL Communications, Inc. 333 Hudson Street, 7th Floor, New York, NY 10013.

One-year subscription rates: domestic \$120; foreign \$185; in-training \$75. For subscriptions: Phone: 212-328-0800; Fax: 212-328-0600; Web: www.cnsspectrums.com.

Postmaster: Send address changes to *CNS Spectrums* c/o PPS Medical Marketing Group 264 Passaic Avenue, Fairfield, NJ 07004-2595.

For editorial inquiries, please fax us at 212-328-0600 or e-mail us at dh@mblcommunications.com.

For bulk reprint purchases, please contact: Christopher Naccari at cdn@mblcommunications.com.

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., or the editorial advisory board. Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums is a registered trademark of CNS Spectrums, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher.

BPA Membership Applied for August 2004. Audit Bureau of Circulations member.

MBL
communications

Copyright ©2004 by MBL Communications, Inc. All rights reserved. Printed in the United States.

EDITORIAL MISSION

CNS Spectrums' editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and original research and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. The journals' goals is to serve as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.